Radiochemotherapy for Lung Cancer in Developing Countries

Clinical Oncology

Volumn 21, Issue 7, 2009, Pages 536-542

  Kepka, L ^a   Casas, F ^b   Perin, B ^c   Abdel Wahab, S ^d   Saghatelyan, T ^e   Vashkevitch, L ^f   Gaye, P M ^g   Dawotola, D ^h   Agarwal, J P ⁱ   Jeremic, B ^j  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Clinic University Hospital   (Spain)

^c Institute for Lung Diseases   (Serbia)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e Department of Radiation Oncology   (Armenia)

^f Research Institute of Oncology and Medical Radiology of the Ministry of Health of the Byelorussian SSR   (Belarus)

^g Dantec   (Senegal)

^h Department of Radiation Oncology ^*  (Nigeria)

ⁱ TATA MEMORIAL HOSPITAL   (India)

^j INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

more..

Author keywords

Chemotherapy; combined treatment; developing countries; elderly; lung cancer; radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL;

ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ELDERLY CARE; ESOPHAGUS DISEASE; FRAIL ELDERLY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEMATOLOGIC DISEASE; HUMAN; LOW DRUG DOSE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SURGERY; METHODOLOGY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE FRACTIONATION; TREATMENT DURATION;

COMBINED MODALITY THERAPY; DEVELOPING COUNTRIES; HUMANS; LUNG NEOPLASMS;

EID: 68049123227     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.04.001     Document Type: Article

References (55)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Alberg A.J., Ford J.G., and Samet J.M. Epidemiology of lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) 29S-55S
3. Kepka L., Danilova V., Saghatelyan T., et al. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer 56 (2007) 235-245
4. Macbeth F.R., Abratt R.P., Cho K.H., Stephens R.J., and Jeremic B. Lung cancer management in limited resource settings: guidelines for appropriate good care. Radiother Oncol 82 (2007) 123-131
5. Scott W.J., Howington J., Feigenberg S., Movsas B., and Pisters K. Treatment of non-small cell lung cancer stage I and stage II. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) 234S-242S
6. Jeremic B., Classen J., and Bamberg M. Radiation therapy alone in technically operable, medically inoperable early stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54 (2002) 119-130
7. Jeremic B., Milicic B., Acimovic L., and Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early stage (I/II) non-small cell lung cancer (NSCLC). Long-term results of a phase II study. J Clin Oncol 23 (2005) 6873-6880
8. Onishi H., Araki T., Shirato H., et al. Stereotactic hypofractionated high-dose irradiation therapy for stage I non-small cell lung carcinoma: clinical outcomes in 245 patients in a Japanese multi-institutional study. Cancer 101 (2004) 1623-1631
9. Timmerman R.D., Kavanagh B.D., Chinsoo Cho L., Papiez L., and Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25 (2007) 947-952
10. Slotman B.J., Antonisse I.E., and Njo K.H. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 41 (1996) 41-44
11. Lester J.F., Macbeth F.R., Brewster A.E., et al. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer 45 (2004) 237-242
12. Aupérin A., Le Péchoux C., Pignon J.P., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 17 (2006) 473-483
13. Rolland E., Le Pechoux C., Curran W.J., et al. Concomitant radio-chemotherapy (CT-RT) versus sequential CT-RT in locally advanced non-small-cell lung cancer (NSCLC): a meta analysis using individual patient data (IPD) from randomized clinical trials (RCTs). Int J Radiat Oncol Biol Phys 69 (2007) 5S
14. Jassem J. The role of radiotherapy in lung cancer: where is the evidence?. Radiother Oncol 83 (2007) 203-213
15. *: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 133 (2007) 243S-265S
16. Rowell N.P., and O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 4 (2004) CD002140.pub2. DOI:10.1002/14651858.CD002140.pub.2
17. Wang S., Liao Z., Wei X., et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66 (2006) 1399-1407
18. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14 (1996) 1065-1070
19. Belderbos J.S.A., Kepka L., Kong Spring F.-M., Martel M.K., Videtic G.M.M., and Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 72 (2008) 335-342
20. De Ruysscher D., Botterweck A., Dirx M., et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 20 (2009) 98-102
21. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbin in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
22. Cakir S., and Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43 (2004) 309-316
23. Demiral A.N., Alicikus Z.A., Ugur V.I., et al. Patterns of care for lung cancer in radiation oncology departments of Turkey. Int J Radiat Oncol Biol Phys 72 (2008) 1530-1537
24. Baumann M., Herrmann T., Koch R., et al. Continuous hyperfractionated accelerated radiotherapy - weekend less (CHARTWEL) versus conventionally fractionated (CF) in non-small-cell lung cancer (NSCLC): first results of a phase III randomised multicentre trial (ARO 97-1). Eur J Cancer 3 (2005) S323
25. Warde P., and Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 6 (1992) 890-895
26. Pignon J.P., Ariagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 327 (1992) 1618-1624
27. Jeremic B., Shibamoto Y., Acimovic L., and Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer. J Clin Oncol 15 (1997) 893-900
28. Takada M., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 20 (2002) 3054-3060
29. Perry M.C., Eaton W.L., Propert K.J., et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316 (1987) 912-918
30. Murray N., Coy P., Pater J., et al. Importance of timing for thoracic P, irradiation in the combined modality treatment of limited stage small cell lung cancer. J Clin Oncol 11 (1993) 336-344
31. Work E., Nielsen O., Bentzen S., et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. J Clin Oncol 15 (1997) 3030-3037
32. Skarlos D.V., Samantas E., Briassoulis E., et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 12 (2001) 1231-1238
33. Fried D.B., Morris D.E., Poole C., et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22 (2004) 4785-4793
34. Huncharek M., and McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9 (2004) 665-672
35. Pijls-Johannesma M.C.G., de Ruysscher D., Lambin P., et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 1 (2005) CD004700
36. Jeremic B. Timing of concurrent radiotherapy (RT) and chemotherapy (CHT) in limited disease small cell lung cancer (LD SCLC). Meta-analysis of meta- analyses. Int J Radiat Oncol Biol Phys 64 (2006) 981-982
37. Turrisi III A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 2650-2671
38. Videtic G.M., Truong P.T., Dar A.R., Yu E.W., and Stitt L.W. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Int J Radiat Oncol Biol Phys 57 (2003) 709-716
39. Jeremic B., Shibamoto Y., Nikolic N., et al. The role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer (ED SCLC): a randomized study. J Clin Oncol 17 (1999) 2092-2099
40. Aupérin A., Arriagada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 (1999) 476-484
41. Slotman B., Faivre-Finn C., Kramer G., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 (2007) 664-672
42. Schild S.E., Stella P.J., Geyer S.M., et al. The outcome of combined modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21 (2003) 3201-3206
43. Kusumoto S., Koga K., Tsukino H., Nagamachi S., Nishikawa K., and Watanabe K. Comparison of survival of patients with lung cancer between elderly (greater than or equal to 70) and younger (70 greater than) age groups. Jpn J Clin Oncol 16 (1986) 319-323
44. Schaake-Koning C., van der Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326 (1992) 524-530
45. Jeremic B., Shibamoto Y., Acimovic L., and Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 13 (1995) 452-458
46. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 50 (2001) 19-25
47. Pignon T., Gregor A., Schaake Koning C., Roussel A., Van Glabbeke M., and Scalliet P. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 46 (1998) 239-248
48. Movsas B., Scott C., Sause W., et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 45 (1999) 1143-1149
49. Jeremic B., Shibamoto Y., Milicic B., et al. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/oral etoposide in elderly patients with stage III non-small-cell lung cancer. A phase II study. Int J Radiat Oncol Biol Phys 44 (1999) 343-348
50. Quon H., Shepherd F.A., Payne D.G., et al. The influence of age on the delivery tolerance and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 43 (1999) 39-45
51. Yuen A.R., Zou G., Turrisi A.T., et al. Similar outcome of elderly patients in Intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 89 (2000) 1953-1960
52. Schild S.E., Stella B.J., Brooks B.J., et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 103 (2005) 2349-2354
53. Jeremic B., Shibamoto Y., Acimovic L., and Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung cancer. A phase II study. Cancer 82 (1998) 836-841
54. Murray N., Grafton C., Shah A., et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 16 (1998) 3323-3328
55. NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer. Available from:. www.nccn.org